These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17584139)

  • 21. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How a single inversion of configuration leads to a reversal of the binding mode: proposal of a novel arrangement of CCK2 ligands in their receptor, and contribution to the development of peptidomimetic or non-peptide CCK2 ligands.
    Bellier B; Garbay C
    Eur J Med Chem; 2003; 38(7-8):671-86. PubMed ID: 12932898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly constrained dipeptoid analogues containing a type II' beta-turn mimic as novel and selective CCK-A receptor ligands.
    de la Figuera N; Martín-Martínez M; Herranz R; García-López MT; Latorre M; Cenarruzabeitia E; del Río J; González-Muñiz R
    Bioorg Med Chem Lett; 1999 Jan; 9(1):43-8. PubMed ID: 9990454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Replacement of glycine with dicarbonyl and related moieties in analogues of the C-terminal pentapeptide of cholecystokinin: CCK(2) agonists displaying a novel binding mode.
    Bellier B; Million ME; DaNascimento S; Meudal H; Kellou S; Maigret B; Garbay C
    J Med Chem; 2000 Oct; 43(20):3614-23. PubMed ID: 11020275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benzotriazonine as a new core structure for the design of CCK-receptor antagonists.
    Escherich A; Escrieut C; Fourmy D; Moroder L
    J Pept Sci; 1999 Mar; 5(3):155-8. PubMed ID: 10323559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists.
    Bock MG; DiPardo RM; Newton RC; Bergman JM; Veber DF; Freedman SB; Smith AJ; Chapman KL; Patel S; Kemp JA
    Bioorg Med Chem; 1994 Sep; 2(9):987-98. PubMed ID: 7712133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of cyclic and branched peptide analogues as ligands for cholecystokinin type 1 receptor.
    De Luca S; De Capua A; Saviano M; Della Moglie R; Aloj L; Tarallo L; Pedone C; Morelli G
    Bioorg Med Chem; 2007 Sep; 15(17):5845-53. PubMed ID: 17562367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents.
    Pierson ME; Comstock JM; Simmons RD; Kaiser F; Julien R; Zongrone J; Rosamond JD
    J Med Chem; 1997 Dec; 40(26):4302-7. PubMed ID: 9435899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of CCK2 receptors in the homeostasis of the opioid system.
    Noble F; Roques BP
    Drugs Today (Barc); 2003 Nov; 39(11):897-908. PubMed ID: 14702135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
    J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
    Bignon E; Bachy A; Boigegrain R; Brodin R; Cottineau M; Gully D; Herbert JM; Keane P; Labie C; Molimard JC; Olliero D; Oury-Donat F; Petereau C; Prabonnaud V; Rockstroh MP; Schaeffer P; Servant O; Thurneyssen O; Soubrié P; Pascal M; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1999 May; 289(2):742-51. PubMed ID: 10215648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
    Evans BE; Rittle KE; Bock MG; DiPardo RM; Freidinger RM; Whitter WL; Lundell GF; Veber DF; Anderson PS; Chang RS
    J Med Chem; 1988 Dec; 31(12):2235-46. PubMed ID: 2848124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic and chemical developments of cholecystokinin receptor ligands.
    de Tullio P; Delarge J; Pirotte B
    Expert Opin Investig Drugs; 2000 Jan; 9(1):129-46. PubMed ID: 11060666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor.
    Harikumar KG; Pinon DI; Wessels WS; Prendergast FG; Miller LJ
    J Biol Chem; 2002 May; 277(21):18552-60. PubMed ID: 11893747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of the cholecystokinin-induced depolarization of pacemaking activity in cultured interstitial cells of Cajal from murine small intestine.
    Lee JH; Kim SY; Kwon YK; Kim BJ; So I
    Cell Physiol Biochem; 2013; 31(4-5):542-54. PubMed ID: 23571358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
    Low CM; Black JW; Broughton HB; Buck IM; Davies JM; Dunstone DJ; Hull RA; Kalindjian SB; McDonald IM; Pether MJ; Shankley NP; Steel KI
    J Med Chem; 2000 Sep; 43(19):3505-17. PubMed ID: 11000005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
    Lee YS; Agnes RS; Badghisi H; Davis P; Ma SW; Lai J; Porreca F; Hruby VJ
    J Med Chem; 2006 Mar; 49(5):1773-80. PubMed ID: 16509592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholecystokinin (CCK) assays.
    Trist DG; Corsi M
    Curr Protoc Pharmacol; 2001 May; Chapter 4():Unit 4.13. PubMed ID: 21965069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.